Introduction: Hyperbaric oxygen therapy (HBOT) is the administration of 100% oxygen at pressures greater than 1 atmosphere. One recurrent criticism that has been made of this field is that treatment is based on little or no good clinical evidence. Aims: The primary objective of this thesis is to make a useful response to that criticism. I planned to collate all the available randomised evidence in the fields of diving and hyperbaric medicine, supply a critical appraisal of each paper, and synthesise that evidence in a series of systematic reviews with meta-analysis. I also intended to use a cost analysis of hyperbaric practice in our own facility to inform formal cost-effectiveness analysis using the estimates of effect generated by the individual meta-analyses. Methods: A comprehensive search strategy was used to identify all clinical RCTs involving the administration of hyperbaric breathing mixtures. Each trial was appraised using the software developed by the Oxford Centre for Evidence Based Medicine. Each critical appraisal was loaded onto a searchable web site at www.hboevidence.com. Each diagnostic category identified was considered for inclusion in a Cochrane systematic review and meta-analysis. Results: The database includes 130 critical appraisals covering 173 separate reports. The site has received more than 17,000 hits. There are 12 formal meta-analytical reviews and all have been accepted for publication in the Cochrane Database of Systematic Reviews at the time of writing. These form the basis of this thesis and include late radiation tissue injury, chronic wounds, acute hearing loss and tinnitus, multiple sclerosis and decompression illness. The meta-analyses in this thesis suggest there are several areas where HBOT is associated with improved clinical outcomes and that routine use is probably justified in some areas (e.g. radiation proctitis healing with HBOT: NNT 3, 95%CI 2 to 11). On the other hand, these analyses suggest there is most unlikely to be significant clinical benefit from the application of HBOT to patients currently referred for HBOT (e.g. multiple sclerosis). Conclusions: The randomised evidence for the use of HBOT is now significantly easier to access. Recommendations for therapy and future research directions can be made on the basis of these analyses.

The peer-reviewed publications contained within this thesis describe studies that have contributed significantly to the understanding of long-term oxygen therapy (LTOT) for Australian Chronic Obstructive Pulmonary Disease (COPD) patients. My personal contribution to each of these studies ranged from the initial development of the hypotheses and design and execution of the investigations, submission of research grants applications to fund the studies through to preparation of the manuscripts for publication. When LTOT was first introduced into Australia I was fortunate to meet the key experts in LTOT including Professors Tom Petty, Nick Anthonisen, David Flenley, Pierre Levi-Valensi and Peter Howard. At that time all were involved in randomised controlled trials of oxygen therapy. (1, 2), 3). I also visited several oxygen concentrator and oxygen supply companies in the USA and UK. It was during these visits that I became convinced that the concentrator provided a more economical and efficient method of LTOT delivery. In 1980, an oxygen concentrator was imported to Australia by the spouse of one of our patients suffering from emphysema who was receiving long term oxygen via cylinders In 1982, two oxygen concentrators were donated to FMC by two different manufacturers (DeVilbis and Marx) based in the USA. These instruments were trialled on a male and female patient receiving LTOT in the Southern Adelaide metropolitan area. The initial acceptance of this device by these patients led to a submission to the South Australian Department of Health for a grant to purchase 40 units. Funds were finally obtained for the purchase of 34 concentrators by FMC and these were rolled out to the then existing patients who were receiving LTOT in 1984. Up to this point in time the only published guidelines or recommendations for LTOT came from the American College of Chest Physicians in 1973(3) and the American Thoracic Society in 1977(4). In 1982, the staff of the Respiratory Unit, FMC held a workshop where it was agreed that patients' would be assessed for home oxygen therapy using the 1977 American Thoracic Society Guideline. The late Professor Ann Woolcock presented a paper during a 1983 symposium titled "Long Term Oxygen Therapy: A World View" during a 1983 symposium held in Toronto, Canada where she estimated that at that time 2,100 patients were receiving oxygen in New South Wales for an average of 1 hour per day. She further reported that the use of cylinders ranged from 1 cylinder a year to 14 cylinders per week. Physicians were reported to have been conservative in their approach to oxygen therapy and that only 50 people were on long term oxygen therapy in New South Wales. Presumably the vast majority of these patients were receiving intermittent oxygen therapy. Woolcock mentioned that oxygen concentrators were available but provided no specific detail of their use in Australia(5). The first Australian guideline for the provision of domiciliary long-term oxygen therapy appeared in 1985. This guideline was developed at the request of the Thoracic Society of Australia and New Zealand. 6). In the same year I published my first paper relating to the provision of oxygen therapy via an oxygen concentrator based on our initial experiences with this technology(7). In the following year I published a paper documenting the analysis of the costs for providing home oxygen therapy. I also reported how Cost-Centre Management led to the introduction of practical measures for improved clinical decision making and improved expenditure control resulting in substantial cost savings(8). This publication led to a paper reporting the rationalization of the supply of home oxygen in the Hunter region of New South Wales.(9). This paper also reported the one to five year survival rates for their patients. At that time only between 5 and 12% of patients were receiving LTOT oxygen via an oxygen concentrator. At best, oxygen therapy is cumbersome with the patient 'tethered' to the oxygen source that, in the past, limited the movement of the patient due to the size and weight of the oxygen cylinders. Oxygen concentrators provided a partial answer to these problems. The introduction of this new technology led to ongoing evaluation of the impact on patient care and acceptance of the intervention and whether the expected outcomes increased survival and quality of life, were achieved(10). In 1991 I published the first detailed Australian data on survival for patients receiving home oxygen therapy. The results of this study indicated that the mortality rate for COPD with respiratory failure at 1 year was twice the rate reported by the Medical Research Council Working Party and the Nocturnal Oxygen Therapy multicentre trials. This was in spite of the baseline physiological parameters for our patients being similar to the patients in these benchmark studies. I was later able to show that survival of our long term oxygen patients was no better than the control group of the original MRC study(11-13).The second significant observation was that females survived longer than males(14). In 1992 a further paper was published and reported that in spite of strict prescription criteria and the introduction of a cost-saving new technology oxygen concentrators, the budget for this intervention remained under pressure. This was largely due to a rapidly increasing demand from eligible patients(10).A further analysis of the longitudinal data resulted in a report of an association between home oxygen therapy with a reduction in respiratory admissions and bed days(15). At this time there was a relative paucity of information about the trends of mortality in COPD in Australia. To further understand the burden of disease (COPD) and changing trends in mortality over time a research project was undertaken that indicating that the mortality of females from COPD was increasing whilst it was decreasing in males(16). The relatively poor survival outcomes for our home oxygen patients prompted further attempts to understand the costs and benefits in terms of quality of life and the evaluation of two generic health related quality of life questionnaires available at that time (1996). The results of the study suggested that the sole use of the SF-36 as a health outcome measure in COPD patients might fail to provide information about the mental domains of their quality of life. Decreased cognitive function, anxiety and depression were shown in Australian COPD patients(17). A series of papers published in Europe describing the observations made on Australian home oxygen patients were published between 1996 and 2000 at the request of the International Oxygen Club. The membership of this club included Professors Tom Petty, David Flenley, Pierre Levi-Valensi, Peter Howard, Heinrich Matthys and Roland Keller(11, 18, 19, 20 ). Further attempts to rationally allocate resources in the management of COPD in the acute care setting were reported in 1999 using Program Budgeting and Marginal Analysis. (21). I undertook a systematic Cochrane Review of the five randomized controlled trials of the use of home or long term oxygen therapy in COPD demonstrating that this intervention improved survival in a selected group of severely hypoxaemic COPD patients (22). However, this intervention does not appear to provide any benefit for patients with moderate hypoxaemia or nocturnal desaturation. (20) This review has been translated into several languages and is cited as the basis of many of the more recent guidelines regarding LTOT. More recently a NH&MRC funded study report was published reviewing the impact of evidence based clinical practice concerning LTOT. This report resulted in several peer reviewed papers being published where we explored the relationship between the evidence and the observed outcomes in terms of both survival and quality of life(13, 23, 24). Finally, we conducted a study of the relative survival of our patients compared to those patients with similar characteristics in France. We demonstrated that our patients' relative survival was less than their French counterparts(25). At the time of publication this was only the second paper to be ever-published using relative survival analysis in COPD and the first in Australia. This difference is hard to explain by the level of severity, number of pack years or level of lung function impairment. Other possible factors contributing to the excess mortality in South Australian COPD patients need to be investigated. / Thesis (Ph.D.)--School of Population Health and Clinical Practice, 2005.

Thesis (M. Med. Sc.)--University of Hong Kong, 2001. / Includes bibliographical references (leaves 61-66).

No description available.

The peer-reviewed publications contained within this thesis describe studies that have contributed significantly to the understanding of long-term oxygen therapy (LTOT) for Australian Chronic Obstructive Pulmonary Disease (COPD) patients. My personal contribution to each of these studies ranged from the initial development of the hypotheses and design and execution of the investigations, submission of research grants applications to fund the studies through to preparation of the manuscripts for publication. When LTOT was first introduced into Australia I was fortunate to meet the key experts in LTOT including Professors Tom Petty, Nick Anthonisen, David Flenley, Pierre Levi-Valensi and Peter Howard. At that time all were involved in randomised controlled trials of oxygen therapy. (1, 2), 3). I also visited several oxygen concentrator and oxygen supply companies in the USA and UK. It was during these visits that I became convinced that the concentrator provided a more economical and efficient method of LTOT delivery. In 1980, an oxygen concentrator was imported to Australia by the spouse of one of our patients suffering from emphysema who was receiving long term oxygen via cylinders In 1982, two oxygen concentrators were donated to FMC by two different manufacturers (DeVilbis and Marx) based in the USA. These instruments were trialled on a male and female patient receiving LTOT in the Southern Adelaide metropolitan area. The initial acceptance of this device by these patients led to a submission to the South Australian Department of Health for a grant to purchase 40 units. Funds were finally obtained for the purchase of 34 concentrators by FMC and these were rolled out to the then existing patients who were receiving LTOT in 1984. Up to this point in time the only published guidelines or recommendations for LTOT came from the American College of Chest Physicians in 1973(3) and the American Thoracic Society in 1977(4). In 1982, the staff of the Respiratory Unit, FMC held a workshop where it was agreed that patients' would be assessed for home oxygen therapy using the 1977 American Thoracic Society Guideline. The late Professor Ann Woolcock presented a paper during a 1983 symposium titled "Long Term Oxygen Therapy: A World View" during a 1983 symposium held in Toronto, Canada where she estimated that at that time 2,100 patients were receiving oxygen in New South Wales for an average of 1 hour per day. She further reported that the use of cylinders ranged from 1 cylinder a year to 14 cylinders per week. Physicians were reported to have been conservative in their approach to oxygen therapy and that only 50 people were on long term oxygen therapy in New South Wales. Presumably the vast majority of these patients were receiving intermittent oxygen therapy. Woolcock mentioned that oxygen concentrators were available but provided no specific detail of their use in Australia(5). The first Australian guideline for the provision of domiciliary long-term oxygen therapy appeared in 1985. This guideline was developed at the request of the Thoracic Society of Australia and New Zealand. 6). In the same year I published my first paper relating to the provision of oxygen therapy via an oxygen concentrator based on our initial experiences with this technology(7). In the following year I published a paper documenting the analysis of the costs for providing home oxygen therapy. I also reported how Cost-Centre Management led to the introduction of practical measures for improved clinical decision making and improved expenditure control resulting in substantial cost savings(8). This publication led to a paper reporting the rationalization of the supply of home oxygen in the Hunter region of New South Wales.(9). This paper also reported the one to five year survival rates for their patients. At that time only between 5 and 12% of patients were receiving LTOT oxygen via an oxygen concentrator. At best, oxygen therapy is cumbersome with the patient 'tethered' to the oxygen source that, in the past, limited the movement of the patient due to the size and weight of the oxygen cylinders. Oxygen concentrators provided a partial answer to these problems. The introduction of this new technology led to ongoing evaluation of the impact on patient care and acceptance of the intervention and whether the expected outcomes increased survival and quality of life, were achieved(10). In 1991 I published the first detailed Australian data on survival for patients receiving home oxygen therapy. The results of this study indicated that the mortality rate for COPD with respiratory failure at 1 year was twice the rate reported by the Medical Research Council Working Party and the Nocturnal Oxygen Therapy multicentre trials. This was in spite of the baseline physiological parameters for our patients being similar to the patients in these benchmark studies. I was later able to show that survival of our long term oxygen patients was no better than the control group of the original MRC study(11-13).The second significant observation was that females survived longer than males(14). In 1992 a further paper was published and reported that in spite of strict prescription criteria and the introduction of a cost-saving new technology oxygen concentrators, the budget for this intervention remained under pressure. This was largely due to a rapidly increasing demand from eligible patients(10).A further analysis of the longitudinal data resulted in a report of an association between home oxygen therapy with a reduction in respiratory admissions and bed days(15). At this time there was a relative paucity of information about the trends of mortality in COPD in Australia. To further understand the burden of disease (COPD) and changing trends in mortality over time a research project was undertaken that indicating that the mortality of females from COPD was increasing whilst it was decreasing in males(16). The relatively poor survival outcomes for our home oxygen patients prompted further attempts to understand the costs and benefits in terms of quality of life and the evaluation of two generic health related quality of life questionnaires available at that time (1996). The results of the study suggested that the sole use of the SF-36 as a health outcome measure in COPD patients might fail to provide information about the mental domains of their quality of life. Decreased cognitive function, anxiety and depression were shown in Australian COPD patients(17). A series of papers published in Europe describing the observations made on Australian home oxygen patients were published between 1996 and 2000 at the request of the International Oxygen Club. The membership of this club included Professors Tom Petty, David Flenley, Pierre Levi-Valensi, Peter Howard, Heinrich Matthys and Roland Keller(11, 18, 19, 20 ). Further attempts to rationally allocate resources in the management of COPD in the acute care setting were reported in 1999 using Program Budgeting and Marginal Analysis. (21). I undertook a systematic Cochrane Review of the five randomized controlled trials of the use of home or long term oxygen therapy in COPD demonstrating that this intervention improved survival in a selected group of severely hypoxaemic COPD patients (22). However, this intervention does not appear to provide any benefit for patients with moderate hypoxaemia or nocturnal desaturation. (20) This review has been translated into several languages and is cited as the basis of many of the more recent guidelines regarding LTOT. More recently a NH&MRC funded study report was published reviewing the impact of evidence based clinical practice concerning LTOT. This report resulted in several peer reviewed papers being published where we explored the relationship between the evidence and the observed outcomes in terms of both survival and quality of life(13, 23, 24). Finally, we conducted a study of the relative survival of our patients compared to those patients with similar characteristics in France. We demonstrated that our patients' relative survival was less than their French counterparts(25). At the time of publication this was only the second paper to be ever-published using relative survival analysis in COPD and the first in Australia. This difference is hard to explain by the level of severity, number of pack years or level of lung function impairment. Other possible factors contributing to the excess mortality in South Australian COPD patients need to be investigated. / Thesis (Ph.D.)--School of Population Health and Clinical Practice, 2005.

Thesis (M.Med.Sc.)--University of Hong Kong, 2001. / Includes bibliographical references (leaves 61-66). Also available in print.

No description available.

PURPOSE: This study examined the effects of normobaric oxygen in patients diagnosed with either a Central Retinal Vein Occlusion (CRVO) or Branched Retinal Vein Occlusion (BRVO) who had previously undergone treatment via Anti-VEGF or PRP treatment. The investigation looked into the changes in Macular Thickness (MT) and Visual Acuity (VA). METHODS: This pilot study analyzed patient data from Beth Israel Deaconess Medical Center (Boston, MA) that had been diagnosed with Retinal Vein Occlusions. The patients were brought in and given 3 hours of normobaric oxygen via an oxygen concentrator with imaging and vision checked both before and after the therapy. RESULTS: Eighty-eight percent of our patients in this pilot study saw a decrease in macular thickness after 3-hour oxygen therapy. The mean change in Maximal Macular Thickness was a decrease of 7.1% which was statistically significant when compared to healthy eyes (p<0.001). Additionally, 44% of patients saw an increase in visual acuity, the primary measure of vision. Visual acuity showed a statistically significant change when compared to changes in healthy eyes (p=0.015). No statistical significance was found in the testing of contrast sensitivity nor intraocular pressure. CONCLUSION: Our study showed improvement in central macular thickness and quality of life for individuals using noninvasive normobaric hyperoxia as a treatment for retinal vein occlusions. However, further research is needed to improve the impact of the study and a full randomized control trial should be implemented to further understand the potential impacts of a noninvasive normobaric hyperoxia treatment as a means to alleviate symptoms in retinal vein occlusions. In addition, in the future oxygen supplementation in conjunction with periodic injections of Anti- VEGF could be investigated as a treatment regimen with potential benefits beyond individual therapy. / 2020-06-17T00:00:00Z

No description available.

Thesis (M.S.)--University of Wisconsin--Madison, 1984. / Typescript. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references (leaves 51-53).